

Respiratory infections with *Pseudomonas aeruginosa* in children with Cystic Fibrosis; early surveillance and prevention

Submission date 12/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 20/09/2010	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr G.A. Tramper-Stranders

Contact details
Wilhelmina Kinderziekenhuis
KH.01.419.0
Postbus 85090
Utrecht
Netherlands
3508 AB
+31 (0)30 2504000
g.tramper@umcutrecht.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Acronym

POPeye-study

Study objectives

Our hypothesis is that the initial infection with *P. aeruginosa* occurs at earlier age than previously reported and that prophylactic treatment of *P. aeruginosa*-negative CF-patients will either prevent or delay the first acquisition of *P. aeruginosa* or eradicate the organism before the onset of persistent colonization and accompanying pulmonary inflammatory response.

Please note that as of 12/09/2008, the sources of funding field was updated. The anticipated end date of this trial was also updated. The previous anticipated end date was 01/11/2008.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Multicentre, randomised, double blinded, placebo controlled, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Pulmonary *P. aeruginosa* infection, cystic fibrosis

Interventions

Ciprofloxacin 10 mg/kg orally (po) or matching placebo twice daily (bid) and colistin 1 MIU inhalation or matching placebo bid. Three-monthly courses of three weeks, total study duration 3 years.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Early *P. aeruginosa* colonisation as confirmed by:

1. Persistence of *P. aeruginosa* in sputum or oropharyngeal swab culture in two consecutive samples, taken greater than 3 days apart
2. *P. aeruginosa* in one oropharyngeal swab or sputum culture with pulmonary exacerbation

Secondary outcome measures

Microbiological:

1. Age at first positive culture
2. Time to *P. aeruginosa* colonisation
3. Respiratory pathogens in culture
4. Resistance pattern of respiratory pathogens

Serological:

5. Seroconversion for anti-pseudomonal antibodies

Clinical:

6. Adverse events
7. Clinical parameters (lung function, body weight and chest radiograph scores, inflammation parameters)
8. Number of pulmonary exacerbations
9. Antimicrobial agent use

Overall study start date

01/07/2005

Completion date

01/03/2009

Eligibility**Key inclusion criteria**

1. CF diagnosis as confirmed by sweat chloride test and/or genotyping
2. Aged less than 18 years old
3. No evidence of *P. aeruginosa* in cultures taken in period 2004 - 2005
4. Antibody titer less than 1:1250 for three antigens of *P. aeruginosa*
5. No regular treatment against *P. aeruginosa*
6. Informed consent

Participant type(s)

Patient

Age group

Child

Upper age limit

18 Years

Sex

Both

Target number of participants

100

Key exclusion criteria

1. Aged greater than 18 years
2. P. aeruginosa in cultures after 2003
3. Participating in another trial

Date of first enrolment

01/07/2005

Date of final enrolment

01/03/2009

Locations**Countries of recruitment**

Netherlands

Study participating centre

Wilhelmina Kinderziekenhuis

Utrecht

Netherlands

3508 AB

Sponsor information**Organisation**

University Medical Center Utrecht (UMCU) (The Netherlands)

Sponsor details

Heidelberglaan 100

Utrecht

Netherlands

3584 CX

Sponsor type

Hospital/treatment centre

Website

<http://www.umcutrecht.nl/zorg/>

ROR

<https://ror.org/0575yy874>

Funder(s)

Funder type

Research organisation

Funder Name

Added 12/09/2008:

Funder Name

Initial funding was from the investigator for one year (Netherlands)

Funder Name

Dutch Cystic Fibrosis Foundation (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2010		Yes	No